Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 5/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | HTR7 | P34969 | 5/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10286028 | 0.96 | CHRM4 (0.41) | CHRM4DRD2HTR7ADORA1ADORA2A | |
| SCHEMBL14885003 | 0.96 | CHRM4 (0.41) | CHRM4DRD2HTR7ADORA1ADORA2A | |
| SCHEMBL10286793 | 0.81 | CHRM4 (0.38) | CHRM4DRD2HTR7ALDH1A1 | |
| SCHEMBL10287027 | 0.77 | ADORA1 (0.39) | CHRM4DRD2HTR7ADORA1ADORA2A | |
| SCHEMBL4713765 | 0.77 | HDAC1 (0.43) | CHRM4DRD2HTR7ADORA2AHDAC6 | |
| SCHEMBL10286027 | 0.77 | CHRM4 (0.39) | CHRM4DRD2HTR7ALDH1A1 | |
| SCHEMBL10286480 | 0.76 | CHRM4 (0.39) | CHRM4DRD2HTR7ALDH1A1 | |
| SCHEMBL14885006 | 0.76 | CHRM4 (0.39) | CHRM4DRD2HTR7ALDH1A1 | |
| SCHEMBL10286368 | 0.76 | RAB9A (0.40) | ADORA1ADORA2AADORA3ALDH1A1IRAK4 | |
| SCHEMBL31598496 | 0.76 | RAB9A (0.40) | ADORA1ADORA2AADORA3ALDH1A1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | CHRM4 299/4885DRD2 149/4885HTR7 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.